SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

ORKA-004

ORKA·Oruka Therapeutics, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Preclinical / entering Phase 1
Time to market
ORKA-004 has not yet entered clinical trials. Assuming Phase 1 starts in late 2026 or early 2027, a potential approval would likely be 5-8 years away, if clinical development is successful.
Why 3/10
ORKA-004 has no hard dated catalyst in the next ~12 months. It was expected to enter clinical development in Q4 2026 (per Q2 2026 guidance), but no specific start date, PDUFA, or pivotal readout is scheduled. The company's value is overwhelmingly driven by lead asset ORKA-001 (Phase 2b/3).
Actionable Insight NEUTRAL

Watch for an announcement that ORKA-004 has entered clinical development (expected Q4 2026 per prior guidance). The more impactful near-term catalysts for ORKA stock are the 52-week EVERLAST-A data for ORKA-001 due December 2026 and ORKA-002 Phase 2 data due Q1 2027. ORKA-004 is a pipeline-extender, not a near-term value driver.

Price Chart

Loading chart...

Executive Summary

ORKA-004 is a preclinical-stage half-life extended monoclonal antibody targeting TL1A, being developed by Oruka Therapeutics (NASDAQ: ORKA) for inflammatory bowel disease (IBD). It was expected to enter clinical development in Q4 2026, though no formal announcement of first dosing has been made as of November 9, 2026. ORKA-004 is a pipeline-extending asset; Oruka's primary value driver is ORKA-001, a Phase 2b IL-23p19 inhibitor for psoriasis that has shown best-in-class efficacy. The company holds $1.2B in cash and plans Phase 2 combination studies of ORKA-004 with its other assets starting in 2027. For a non-medical investor, ORKA-004 is too early-stage to be a meaningful standalone catalyst for the stock.

How It Works

ORKA-004 is a half-life extended monoclonal antibody that blocks TL1A, a protein involved in triggering inflammation in the gut. By neutralizing TL1A, the drug aims to reduce the inflammatory cascade that drives inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. The 'half-life extended' design means the drug may stay active in the body longer, potentially allowing less frequent dosing.

Trial Status

ORKA-004 was expected to enter clinical development in Q4 2026 per the company's Q2 2026 corporate update. No first-patient-dosed or IND clearance announcement has been made as of November 9, 2026. The company plans to initiate Phase 2 combination studies with ORKA-001 and ORKA-002 beginning in 2027.

The Two-Sided Case

▲ Bull Case4
ORKA-004 targets TL1A, a validated mechanism in inflammatory bowel disease (IBD), a multi-billion-dollar market with high unmet need.
The half-life extended format could enable less frequent dosing, a potential competitive advantage over existing anti-TL1A antibodies.
Oruka has a $1.2B cash position (as of Q3 2026) to fund development through multiple catalysts, including ORKA-004's entry into the clinic.
The company plans Phase 2 combination studies of ORKA-004 with ORKA-001 and ORKA-002 starting in 2027, exploring novel dual-pathway approaches.
▼ Bear Case4
ORKA-004 is a preclinical/early-stage asset with no clinical data yet; it will take years to generate proof-of-concept data.
The TL1A space is increasingly competitive: Prometheus Biosciences (acquired by Merck) and others are already in late-stage development with anti-TL1A antibodies for IBD.
Oruka's primary focus and value driver is ORKA-001 (psoriasis); ORKA-004 is a smaller pipeline program that receives less attention and resources.
Insider selling by the CEO, General Counsel, and CMO in Q4 2026 (all under 10b5-1 plans) may signal near-term valuation concerns.

Upcoming Catalysts

  • Entry into clinical development (IND clearance / first patient dosed) - expected Q4 2026, not yet announced
  • Phase 2 combination studies with ORKA-001 and ORKA-002 - planned for 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Oruka Therapeutics, Inc. PRESS-RELEASE ORKA ·Originating report

Sources · 7

Hover a chip for the title
1 pulse2.com2 markets.businessinsider.com3 sec.gov4 sec.gov5 sec.gov6 msn.com7 markets.businessinsider.com